These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 25862533)

  • 1. Measurement and analysis of patient attenuation correction factor during radioiodine therapy.
    Soliman K; Alenezi A; Bakkari M; Shirbini H
    Radiat Prot Dosimetry; 2015 Jul; 165(1-4):448-51. PubMed ID: 25862533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of patient attenuation factor for iodine-131 based on direct dose rate measurements from radioiodine therapy patients.
    Soliman K; Alenezi A
    Nucl Med Commun; 2015 Feb; 36(2):125-8. PubMed ID: 25279710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
    Eschner W; Kobe C; Schicha H
    Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma.
    Hänscheid H; Lassmann M; Luster M; Kloos RT; Reiners C
    Endocr Relat Cancer; 2009 Dec; 16(4):1283-9. PubMed ID: 19628649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
    Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
    J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Measurement of ocular lens ionizing radiation exposure after radioiodine therapy].
    Andreeff M; Claussnitzer J; Oehme L; Freudenberg R; Kotzerke J
    Nuklearmedizin; 2012; 51(3):79-83. PubMed ID: 22395665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokinesis-block micronucleus test in patients undergoing radioiodine therapy for differentiated thyroid carcinoma.
    Popova L; Hadjidekova V; Hadjieva T; Agova S; Vasilev I
    Hell J Nucl Med; 2005; 8(1):54-7. PubMed ID: 15886755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Exposure of relatives of patients after stationary radioiodine therapy by inhalation of 131I in their homes].
    Wellner U; Eschner W; Hillger HW; Schicha H
    Nuklearmedizin; 1998 May; 37(3):113-9. PubMed ID: 9604232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of external radiation dose to caregivers of patients treated with radioiodine after thyroidectomy.
    Jeong KH; Jung JW; Kim CB; Ahn BC; Lee HK; Yoo SJ; Day O; Lee JK
    Health Phys; 2014 Apr; 106(4):466-74. PubMed ID: 24562067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evaluation of urine activity and external dose rate from patients receiving radioiodine therapy for thyroid cancer.
    Demir M; Parlak Y; Cavdar I; Yeyin N; Tanyildizi H; Gümüser G; Sayit E; Erees S; Sayman H
    Radiat Prot Dosimetry; 2013; 156(1):25-9. PubMed ID: 23535081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A practical guideline for the release of patients treated by I-131 based on Monte Carlo dose calculations for family members.
    Han EY; Lee C; Mcguire L; Bolch WE
    J Radiol Prot; 2014 Jun; 34(2):N7-17. PubMed ID: 24705486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective method of measuring the radioactivity of [ 131I]-capsule prior to radioiodine therapy with significant reduction of the radiation exposure to the medical staff.
    Lützen U; Zhao Y; Marx M; Imme T; Assam I; Siebert FA; Culman J; Zuhayra M
    J Appl Clin Med Phys; 2016 Jul; 17(4):59-72. PubMed ID: 27455475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exhalation of
    Sudbrock F; Fischer T; Zimmermanns B; Drzezga A; Schomäcker K
    J Environ Radioact; 2017 Jan; 166(Pt 1):162-165. PubMed ID: 27405239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretherapeutic dosimetry before 131I therapy of benign thyroid disease. A clinical practice assessment of dosimetric parameters.
    Krohn T; Behrendt FF; Heinzel A; Müller B; Mottaghy FM; Verburg FA
    Nuklearmedizin; 2015; 54(3):131-6. PubMed ID: 25487217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NRC absorbed dose reconstruction for family member of 131I therapy patient: case study and commentary.
    Marcus CS; Siegel JA
    J Nucl Med; 2004 Apr; 45(4):13N-6N, 37N. PubMed ID: 15073236
    [No Abstract]   [Full Text] [Related]  

  • 16. Radiation Safety Precautions in (131)I Therapy of Graves' Disease Based on Actual Biokinetic Measurements.
    Liu B; Tian R; Peng W; He Y; Huang R; Kuang A
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2934-41. PubMed ID: 26046966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An engagement factor for caregiver radiation dose assessment with radioiodine treatment.
    Lee HK; Hong SJ; Jeong KH; Jung JW; Kim SM; Kang YH; Han MS
    Radiat Prot Dosimetry; 2015 Mar; 163(4):499-508. PubMed ID: 25028695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation exposure rate from 131I-treated hyperthyroid patients--a dynamic study, with data for up to 42 d post therapy.
    Mohammadi H
    Health Phys; 2005 May; 88(5):486-90. PubMed ID: 15824597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Measurement of incorporation in family members of radioiodine therapy patients after therapy of benign thyroid diseases].
    Lassmann M; Hänscheid H; Schelper LF; Körber C; Reiners C
    Nuklearmedizin; 1998 May; 37(3):120-3. PubMed ID: 9604233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioiodine therapy: care of the helpless patient and handling of the radioactive corpse.
    Greaves C; Tindale W
    J Radiol Prot; 2001 Dec; 21(4):381-92. PubMed ID: 11787894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.